

# **Prof. NURULLAH ZENGİN**

## **Personal Information**

**Email:** nurullah.zengin@lokmanhekim.edu.tr  
**Web:** <https://avesis.lokmanhekim.edu.tr/nurullah.zengin>

## **International Researcher IDs**

**ScopusID:** 6701914482  
**Yoksis Researcher ID:** 164247

## **Education Information**

Associate Degree, Ankara University, Tıp Fakültesi, Tıp Pr., Turkey 1984 - 1990

## **Academic Titles / Tasks**

Professor, Erzincan Binali Yıldırım University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2011 - Continues

## **Advising Theses**

ZENGİN N., Özofagus kanserli hastalarda prognostik faktörlerin değerlendirilmesi, Expertise In Medicine, M.PAMUKÇUOĞLU(Student), 2009  
ZENGİN N., Mide kanserinde prognostik faktörler, Expertise In Medicine, K.ULUDAĞ(Student), 2005

## **Published journal articles indexed by SCI, SSCI, and AHCI**

- I. **Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome**  
YAZICI O., Ucar G., SÜTCÜOĞLU O., Turhal N. S., Yıldız B., Karamouzis M., Yavuz S., Karadurmuş N., ZENGİN N., Geva R., et al.  
Current Medical Research and Opinion, vol.38, pp.579-586, 2022 (SCI-Expanded)
- II. **Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE**  
Gunes A. K., Dagdas S., Ceran F., Ucar M. A., Falay M., Sunu C., Ayli M., ZENGİN N., Ozet G.  
Indian Journal of Hematology and Blood Transfusion, vol.37, no.1, pp.82-89, 2021 (SCI-Expanded)
- III. **Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder**  
Erdem G. U., Dogan M., Aytekin A., Sahin S., Cinkir H. Y., Sakin A., Ozcelik M., Bozkurt O., Sezer E., Demirci N. S., et al.  
Irish Journal of Medical Science, vol.189, no.2, pp.431-438, 2020 (SCI-Expanded)
- IV. **A rare case: Branch retinal vein occlusion associated with the use of tamoxifen**  
DEMİRCİ N. S., Erdem G., Uçgun N., Bozkaya Y., Ozdemir N., Dogan M., ZENGİN N.  
Journal of Cancer Research and Therapeutics, vol.15, no.3, pp.722-724, 2019 (SCI-Expanded)
- V. **The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy**  
Sahin T., Dizdar O., Ozdemir N., ZENGİN N., Ates O., Oksuzoglu B., ŞENDUR M. A. N., Bilgin B., DEMİR M., Bozbulut U. B., et al.  
Anti-Cancer Drugs, vol.30, no.3, pp.289-294, 2019 (SCI-Expanded)

- VI. **Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients**  
Bozkaya Y., Erdem G. U., DEMİRCİ N. S., Yazıcı O., Özdemir N. Y., Köstek O., ZENGİN N.  
Current Medical Research and Opinion, vol.35, no.2, pp.275-282, 2019 (SCI-Expanded)
- VII. **Is the Charlson comorbidity index a prognostic indicator for toxicity and mortality in elderly patients with locally advanced rectal cancer?**  
Köstek O., Bozkaya Y., Hacıoğlu M. B., Özdemir N. Y., Yılmaz E., Demircan N. C., ERDOĞAN B., UZUNOĞLU S., ÇİÇİN İ., ZENGİN N.  
Archives of Iranian Medicine, vol.22, no.5, pp.236-241, 2019 (SCI-Expanded)
- VIII. **Mortality risk analysis of asymptomatic and symptomatic venous thromboembolism in patients with metastatic colorectal cancer**  
Bozkaya Y., Özdemir N., Erdem G., DEMİRCİ N. S., Yazıcı O., Hocazade C., ZENGİN N.  
Journal of Cancer Research and Therapeutics, vol.14, no.6, pp.1330-1335, 2018 (SCI-Expanded)
- IX. **Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer?**  
Dogan M., Algin E., Guven Z. T., Baykara M., Kos T. F., Bal O., ZENGİN N.  
Current Medical Research and Opinion, vol.34, no.5, pp.857-863, 2018 (SCI-Expanded)
- X. **Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder**  
Erdem G. U., Dogan M., Sakin A., Oruc Z., Yaman E., Yesil Cinkir H., Uysal M., Bozkurt O., Ozturk B., Aytekin A., et al.  
Oncology Research and Treatment, vol.41, no.4, pp.220-225, 2018 (SCI-Expanded)
- XI. **Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?**  
Bozkaya Y., Özdemir N. Y., Sezer S., Köstek O., DEMİRCİ N. S., Yazıcı O., Erdem G. U., Eren T., ZENGİN N.  
Cancer Biomarkers, vol.22, no.1, pp.143-149, 2018 (SCI-Expanded)
- XII. **5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane**  
Erdem G. U., Bozkaya Y., Ozdemir N. Y., DEMİRCİ N. S., Yazıcı O., ZENGİN N.  
Bosnian Journal of Basic Medical Sciences, vol.18, no.2, pp.170-177, 2018 (SCI-Expanded)
- XIII. **Preoperative platelet-to-lymphocyte ratio is a predictor of prognosis in patients with ampullary carcinoma**  
DEMİRCİ N. S., Ozdemir N., Erdem G., Bozkaya Y., Yazıcı O., ZENGİN N.  
Bratislava Medical Journal, vol.119, no.3, pp.180-186, 2018 (SCI-Expanded)
- XIV. **Advanced signet-ring cell carcinoma of the stomach: Clinicopathological characteristics of patients and efficacy of the modified docetaxel, cisplatin, and fluorouracil regimen**  
Bozkaya Y., Erdem G. U., Özdemir N. Y., Hocazade C., Yazıcı O., DEMİRCİ N. S., ZENGİN N.  
Journal of Cancer Research and Therapeutics, vol.14, no.10, 2018 (SCI-Expanded)
- XV. **A modified epirubicin and oxaliplatin plus capecitabine (EOX) regimen as a second- line therapy in patients with advanced gastric cancer**  
Bozkaya Y., Özdemir N. Y., Yazıcı O., DEMİRCİ N. S., Kurtipek A., Erdem G. U., Ergün Y., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.19, no.1, pp.283-290, 2018 (SCI-Expanded)
- XVI. **Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: A retrospective analysis**  
Ergun Y., Ozdemir N. Y., Guner E. K., Esin E., Sendur M. A., Koksoy E. B., Demirci N. S., Eren T., Dede I., Sezer A., et al.  
Journal of B.U.ON., vol.23, pp.116-121, 2018 (SCI-Expanded)
- XVII. **Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center**  
Bozkaya Y., Uncu D., Dağdaş S., Erdem G. U., Doğan M., Özeti G., ZENGİN N.  
Indian Journal of Hematology and Blood Transfusion, vol.33, no.3, pp.361-369, 2017 (SCI-Expanded)
- XVIII. **Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer**  
Bozkaya Y., Doğan M., Umut Erdem G., Tulunay G., Uncu H., Arik Z., Demirci U., Yazıcı O., ZENGİN N.

- Journal of Obstetrics and Gynaecology, vol.37, no.5, pp.649-654, 2017 (SCI-Expanded)
- XIX. **Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy**  
Bozkaya Y., Ozdemir N., Colak A., ZENGİN N.  
Journal of B.U.ON, vol.22, no.4, pp.919-925, 2017 (SCI-Expanded)
- XX. **Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?**  
DEMİRCİ N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., Kilickap S., Cigirgan L. C., Kayacetin E., Bozkaya Y., ZENGİN N.  
Saudi Journal of Gastroenterology, vol.23, no.3, pp.183-189, 2017 (SCI-Expanded)
- XXI. **Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation**  
Yorulmaz A., Dogan M., Artuz F., ZENGİN N.  
Cutaneous and Ocular Toxicology, vol.36, no.2, pp.135-139, 2017 (SCI-Expanded)
- XXII. **Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study**  
Demirci N. S., Aksoy S., Özdemir N. Y., Erdem G. U., Ozcelik M., Tanrikulu E., Eren T., Bozkaya Y., Sahin S., Başol F., et al.  
Current Medical Research and Opinion, vol.33, no.3, pp.401-407, 2017 (SCI-Expanded)
- XXIII. **Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer**  
Erdem G. U., Altundag K., Ozdemir N. Y., Sahin S., Demirci N. S., Karatas F., Bozkaya Y., Aytekin A., Tasdemir V., Asian A. C., et al.  
Journal of B.U.ON, vol.22, no.2, pp.365-376, 2017 (SCI-Expanded)
- XXIV. **Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach**  
Bozkaya Y., Erdem G. U., Özdemir N. Y., DEMİRCİ N. S., Hocazade C., Yazıcı O., ZENGİN N.  
Current Medical Research and Opinion, vol.33, no.1, pp.109-116, 2017 (SCI-Expanded)
- XXV. **A new angiogenesis prognostic index with VEGFA, PLGF, and angiopoietin 1 predicts survival in patients with advanced gastric cancer**  
Aktaş S. H., AKBULUT H., Yazici O., ZENGİN N., Akgün H. N., Üstüner Z., İçli F.  
Turkish Journal of Medical Sciences, vol.47, no.2, pp.399-406, 2017 (SCI-Expanded)
- XXVI. **The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma**  
Bozkaya Y., Doğan M., Yazıcı O., Erdem G. U., DEMİRCİ N. S., ZENGİN N.  
Bosnian Journal of Basic Medical Sciences, vol.17, no.2, pp.138-143, 2017 (SCI-Expanded)
- XXVII. **Adding chemotherapy after neoadjuvant chemoradiation in locally advanced rectal cancer; Promising or not?**  
SENDUR M. A. N., Bilgin B., AKSOY S., Akinci B., Ozdemir N., Dede D. S., YALÇIN B., ZENGİN N.  
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.27, no.3, pp.194-196, 2017 (SCI-Expanded)
- XXVIII. **Prognostic effect of symptomatic and asymptomatic venous thromboembolism in patients with gastric cancer Mide kanserli hastalarda semptomatik ve asemptomatik venöz tromboembolizmin prognostik etkisi**  
Bozkaya Y., Ozdemir N., DEMİRCİ N. S., Erdem G. U., Yazici O., Arslan S., ZENGİN N.  
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.27, no.2, pp.100-109, 2017 (SCI-Expanded)
- XXIX. **Reduced doses of docetaxel and cisplatin plus 5 fluorouracil combination chemotherapy in metastatic esophagogastric adenocarcinoma: The impact on outcomes Metastatik özofagogastrik adenokarsinolarda modifiye doz dosetaksel-sisplatin-5-fluorourasil kombinasyon tedavisi: Sonuçlara etkisi**  
Eren T., Ozdemir N., Yazici O., Imamoglu G. I., Yazilitas D., ARSLAN S. O., ZENGİN N.  
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.27, no.3, pp.171-177, 2017 (SCI-Expanded)
- XXX. **Flare phenomenon in advanced colorectal cancer: Cessation of bevacizumab after predefined cycles of therapy may not affect outcome İleri evre kolorektal kanserli hastalarda alevlenme fenomeni:**

- Önceden belirlenmiş sayıda verilen bevasizumabin kesilmesi sağkalımı olumsuz etkilemeyebilir**  
Besen A. A., Kose F., Sumbul A. T., Ozdemir N., Ozyilkan O., ZENGİN N., Abali H.  
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.27, no.1, pp.53-59, 2017 (SCI-Expanded)
- XXXI. The clinical and pathological features affecting the time of relapse in patients with early stage colorectal cancer**  
Yazilitas D., Özdemir N., Yazici O., Hocazade C., DEMİRCİ N. S., ZENGİN N.  
Journal of Cancer Research and Therapeutics, vol.12, no.4, pp.1257-1260, 2016 (SCI-Expanded)
- XXXII. Accessory spleen hypertrophy mimicking colon cancer metastasis**  
Ates I., Yazici O., Yazilitas D., Ozdemir N., ZENGİN N.  
Experimental Oncology, vol.38, no.3, pp.202-203, 2016 (SCI-Expanded)
- XXXIII. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer**  
Kos M., Hocazade C., Kos F. T., Uncu D., Karakas E., Dogan M., Uncu H. G., Yildirim N., ZENGİN N.  
Wiener Klinische Wochenschrift, vol.128, no.17-18, pp.635-640, 2016 (SCI-Expanded)
- XXXIV. Impact of laboratory test use strategies in a Turkish hospital**  
Yilmaz F. M., Kahveci R., Aksoy A., Kucuk E. Ö., Akin T., Mathew J. L., Meads C., ZENGİN N.  
PLoS ONE, vol.11, no.4, 2016 (SCI-Expanded)
- XXXV. Oxaliplatin-induced acute thrombocytopenia**  
Erdem G., Dogan M., DEMİRCİ N. S., ZENGİN N.  
Journal of Cancer Research and Therapeutics, vol.12, no.2, pp.509-514, 2016 (SCI-Expanded)
- XXXVI. Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology**  
Ozcelik M., Seker M., Eraslan E., Koca S., Yazilitas D., Ercelep O., Ozaslan E., Kaya S., Hacibekiroglu I., Menekse S., et al.  
Tumor Biology, vol.37, no.4, pp.5231-5237, 2016 (SCI-Expanded)
- XXXVII. Small cell carcinoma of the urinary bladder: Changing trends in the current literature**  
Erdem G. U., Özdemir N. Y., DEMİRCİ N. S., Şahin S., Bozkaya Y., ZENGİN N.  
Current Medical Research and Opinion, vol.32, no.6, pp.1013-1021, 2016 (SCI-Expanded)
- XXXVIII. The effect of the gastrectomy on survival in patients with metastatic gastric cancer: A study of ASMO**  
Yazici O., Özdemir N., Duran A. O., Menekşe S., Nahit Sendur M. A., Karaca H., Göksel G., Arpacı E., Hacibekiroğlu I., Bilgetekin I., et al.  
Future Oncology, vol.12, no.3, pp.343-354, 2016 (SCI-Expanded)
- XXXIX. First hematopoietic cell transplantation in Uzbekistan: Progress through education and cooperation**  
Karimov K., Tekgündüz E., Saidov A., Kayıkçı Ö., Boboev K., Koçubaba Ş., Kayumov A., Kılıç A., Adibelli G., Isroilov A., et al.  
Transfusion and Apheresis Science, vol.54, no.1, pp.60-62, 2016 (SCI-Expanded)
- XL. Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor positive breast cancer**  
SENDUR M. A. N., AKSOY S., Ozdemir N. Y., ZENGİN N., Yazici O., Sever A. R., Altundag K.  
Journal of B.U.ON., vol.21, no.1, pp.27-34, 2016 (SCI-Expanded)
- XLI. Targeted therapies are new hope for patients with spinal radionecrosis**  
Hocazade C., Ozdemir N. Y., Yazici O., Oztekin Z. N., ZENGİN N.  
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.26, no.2, pp.126-128, 2016 (SCI-Expanded)
- XLII. A retrospective comparison of early stage primary extranodal with nodal non-Hodgkin lymphoma patients: A single center experience**  
Yazilitas D., Özdemir N., Hocazade C., Bozkaya Y., Yazici O., SENDUR M. A. N., ZENGİN N.  
Journal of B.U.ON., vol.20, no.6, pp.1526-1533, 2015 (SCI-Expanded)
- XLIII. A rare case: Hallucination associated with pazopanib**  
DEMİRCİ N. S., Erdem G. U., Dogan M., Ozdemir N. Y., ZENGİN N.  
Journal of Cancer Research and Therapeutics, vol.11, no.4, pp.961-962, 2015 (SCI-Expanded)
- XLIV. Squamous cell and neuroendocrine carcinoma of esophagus: Collision versus composite tumor: A case report and review of literature**  
Yazici O., AKSOY S., Ozhamam E., ZENGİN N.

- Indian Journal of Cancer, vol.52, no.4, pp.603-604, 2015 (SCI-Expanded)
- XLV. Rectal cancer with metastasis to the face**  
Yazilitas D., Dogan M., Ileri A. B., Ozdemir N., DEMİRCİ N. S., ZENGİN N.  
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.25, no.2, pp.145-147, 2015 (SCI-Expanded)
- XLVI. Unusual metastases of lung cancer: bulbus oculi and maxillary sinus**  
Ates I., Yazici O., Ates H., Ozdemir N., ZENGİN N.  
Experimental oncology, vol.37, no.3, pp.231-232, 2015 (SCI-Expanded)
- XLVII. The relationship between platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and survival in metastatic gastric cancer on firstline modified docetaxel and cisplatinum plus 5 Fluorourasil Regimen: A single institute experience**  
Dogan M., Eren T., Ozdemir N., Cigirgan C. L., ZENGİN N.  
Saudi Journal of Gastroenterology, vol.21, no.5, pp.320-324, 2015 (SCI-Expanded)
- XLVIII. Concordance of positron emission tomography and computed tomography in patients with locally advanced gastric and esophageal cancer**  
Hocazade C., Özdemir N., Yazici O., Bozkaya Y., Yazılıtaş D., Toptaş Ş., ZENGİN N., Deren T.  
Annals of Nuclear Medicine, vol.29, no.7, pp.621-626, 2015 (SCI-Expanded)
- XLIX. The effect of obesity on recurrence pattern in early breast cancer patients**  
Yazici O., AKSOY S., Sendur M. A. N., Babacan T., Ozdemir N., Ozisik Y., ZENGİN N., Altundag K.  
Journal of B.U.ON, vol.20, no.4, pp.954-962, 2015 (SCI-Expanded)
- L. Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer**  
ŞENDUR M. A. N., AKINCI M. B., Ozdemir N. Y., AKSOY S., Dede D. S., Ulas A., ZENGİN N., YALÇIN B.  
Future Oncology, vol.11, no.8, pp.1141-1143, 2015 (SCI-Expanded)
- L.I. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma**  
Erdem G. U., Sendur M. A. N., Ozdemir N. Y., Yazici O., ZENGİN N.  
Current Medical Research and Opinion, vol.31, no.4, pp.743-756, 2015 (SCI-Expanded)
- L.II. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer**  
ŞENDUR M. A. N., AKSOY S., YORGUN H., Ozdemir N., Yilmaz F. M., Yazici O., Zungun C., AYTEMİR K., ZENGİN N., Altundag K.  
Current Medical Research and Opinion, vol.31, no.3, pp.547-556, 2015 (SCI-Expanded)
- L.III. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer**  
Nahit Şendur M. A., AKSOY S., Bülent Akinci M., Ozdemir N., ŞENER DEDE D., Altundag K., ZENGİN N., YALÇIN B.  
Future Oncology, vol.11, no.6, pp.905-907, 2015 (SCI-Expanded)
- L.IV. Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer: A retrospective study of the Anatolian Society of Medical Oncology**  
Yazilitas D., ŞENDUR M. A. N., Karaca H., Ozdemir N., AKSOY S., Berk V., Yazici O., Oztürk B., Ozkan M., ZENGİN N., et al.  
Asian Pacific Journal of Cancer Prevention, vol.16, no.4, pp.1471-1477, 2015 (SCI-Expanded)
- LV. Duodenal adenocarcinoma: A rare cause of chyloperitoneum (chyloous ascites)**  
Civelek B., AKSOY S., Kos T., Arik Z., Akinci M., Uncu D., Özdemir N., Cihan S., ZENGİN N.  
Indian Journal of Cancer, vol.52, no.1, pp.109, 2015 (SCI-Expanded)
- LVI. Trastuzumab-based retreatment after lapatinib in heavily pretreated HER2 positive metastatic breast cancer: An anatolian society of medical oncology study**  
Uncu D., Bayoglu I. V., Arslan U. Y., Kucukoner M., Artac M., Koca D., Oguz A., Demirci U., Arpacı E., Dogan M., et al.  
Asian Pacific Journal of Cancer Prevention, vol.16, no.9, pp.4127-4131, 2015 (SCI-Expanded)
- LVII. Assessment of prognostic value of "neutrophil to lymphocyte ratio" and "prognostic nutritional index" as a systemic inflammatory marker in non-small cell lung cancer**  
Kos F. T., Hocazade C., Kos M., Uncu D., Karakas E., Dogan M., Uncu H. G., Ozdemir N., ZENGİN N.

- Asian Pacific Journal of Cancer Prevention, vol.16, no.9, pp.3997-4002, 2015 (SCI-Expanded)
- LVIII. **Association between blood urea nitrogen/albumin ratio and prognosis in non-small cell lung cancer**  
Kos M., Hocazade C., Kos F. T., Uncu D., Karakas E., Dogan M., Yildirim N., ZENGİN N.  
Acta Medica Mediterranea, vol.31, no.2, pp.219-223, 2015 (SCI-Expanded)
- LIX. **The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration**  
ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Yazici O., ZENGİN N., Altundag K.  
Current Medical Research and Opinion, vol.30, no.12, pp.2535-2542, 2014 (SCI-Expanded)
- LX. **Lanreotide in metastatic enteropancreatic neuroendocrine tumors**  
Ozdemir N., Yazici O., ZENGİN N.  
New England Journal of Medicine, vol.371, no.16, pp.1555-1557, 2014 (SCI-Expanded)
- LXI. **Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma**  
Civelek B., AKSOY S., Sendur M. A. N., Yazici O., Kanmaz H., Kos F. T., Yildirim N., Uncu D., ZENGİN N.  
Journal of B.U.ON, vol.19, no.4, pp.906-912, 2014 (SCI-Expanded)
- LXII. **The clinicopathological characteristics with long-term outcomes in malignant mesothelioma**  
Dogan M., UTKAN G., Hocazade C., Uncu D., Toptas S., Ozdemir N., ZENGİN N., Icli F.  
Medical Oncology, vol.31, no.10, pp.1-6, 2014 (SCI-Expanded)
- LXIII. **Metastatic parenchymal renal squamous cell carcinoma with hypercalcemia**  
Açıkgoz Y., ŞENDUR M. A. N., AKSOY S., Özdemir N. Y., ZENGİN N.  
Medical Oncology, vol.31, no.9, pp.1-2, 2014 (SCI-Expanded)
- LXIV. **Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen**  
Sendur M. A. N., Ozdemir N., Özath T., Yazıcı O., Aksoy S., Ekinci A. Ş., Yazılıtaş D., Günaydin Y., Oksuzoglu B., Benekli M., et al.  
Medical Oncology, vol.31, no.9, pp.1-8, 2014 (SCI-Expanded)
- LXV. **Impact of acetylsalicylic acid on the clinicopathological characteristics and prognosis of patients with invasive breast cancer**  
Sendur M. A., AKSOY S., Ozdemir N. Y., ZENGİN N., Altundag K.  
Breast Care, vol.9, no.4, pp.261-266, 2014 (SCI-Expanded)
- LXVI. **Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer**  
Şendur M. A. N., Uncu D., ZENGİN N.  
Medical Oncology, vol.31, no.4, 2014 (SCI-Expanded)
- LXVII. **Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer**  
Şendur M. A. N., AKSOY S., Yazici O., Ozdemir N. Y., ZENGİN N., Altundag K.  
Medical Oncology, vol.31, no.2, 2014 (SCI-Expanded)
- LXVIII. **Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma**  
Şendur M. A., AKSOY S., Özdemir N. Y., ZENGİN N.  
Indian Journal of Pharmacology, vol.46, no.1, pp.125-126, 2014 (SCI-Expanded)
- LXIX. **A comparative study of low-profile and regular type totally implantable venous access devices in patients with malignant tumors: Retrospective analysis of 4501 implantations**  
Malign tümörlü olgularda düşük profilli ve standard tip TiVEC kullanı{dotless}mi{dotless}ni{dotless}n  
karşı{dotless}laştı{dotless}rmali{dotless} çali{dotless}şması{dotless}: 4501 olgunun retrospektif analizi  
Akmangit I., Dede D., Daglioglu E., Sayın B., Peker A., Uncu D., ZENGİN N.  
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.24, no.2, pp.97-105, 2014 (SCI-Expanded)
- LXX. **Evaluation of erectile dysfunction risk factors in young male survivors of colorectal cancer**  
Sendur M. A. N., AKSOY S., Ozdemir N. Y., Yaman S., Yazici O., AKINCI M. B., Uncu D., ZENGİN N., Altundag K.  
Journal of B.U.ON, vol.19, no.1, pp.115-123, 2014 (SCI-Expanded)

- LXXI. **Clinicopathologic features and prognosis of osteosarcoma in Turkish adults**  
Seker M. M., Seker A., AKSOY S., Ozdemir N., Uncu D., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.15, no.8, pp.3537-3540, 2014 (SCI-Expanded)
- LXXII. **Everolimus: A new hope for patients with breast cancer**  
Sendur M. A., ZENGİN N., AKSOY S., Altundag K.  
Current Medical Research and Opinion, vol.30, no.1, pp.75-87, 2014 (SCI-Expanded)
- LXXIII. **Effect of port-care frequency on venous port catheter-related complications in cancer patients**  
Odabas H., Ozdemir N. Y., Ziraman I., AKSOY S., Abali H., Oksuzoglu B., Isik M., Civelek B., Dede D., ZENGİN N.  
International Journal of Clinical Oncology, vol.19, no.4, pp.761-766, 2014 (SCI-Expanded)
- LXXIV. **Treatment and outcomes of ewing sarcoma in Turkish Adults: A single centre experience**  
Seker M. M., Kos T., Ozdemir N., Seker A., AKSOY S., Uncu D., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.15, no.1, pp.327-330, 2014 (SCI-Expanded)
- LXXV. **Prognostic factors in operated stage IIIC, pathological N3a breast cancer patients**  
Turker I., Arslan U. Y., Yazici O., Uyeturk U., Oksuzoglu B., Budakoglu B., Özdemir N., Sonmez O. U., Helvacı K., Esbah O., et al.  
Breast Care, vol.9, no.6, pp.421-427, 2014 (SCI-Expanded)
- LXXVI. **Analysis of resected gastric cancer in Turkish population.**  
Demir G., Unsal D., ZENGİN N., Er O., Dane F., Yalçın S., Turkish Oncology Group O.  
Hepato-gastroenterology, vol.61, no.129, pp.259-266, 2014 (SCI-Expanded)
- LXXVII. **Current approaches for prophylactic cranial irradiation in extrapulmonary small cell carcinoma**  
Yazici O., Ozdemir N. Y., Sendur M. A., AKSOY S., ZENGİN N.  
Current Medical Research and Opinion, vol.30, no.7, pp.1327-1336, 2014 (SCI-Expanded)
- LXXVIII. **Acupuncture as a complementary treatment for cancer patients receiving chemotherapy**  
Tas D., Uncu D., Sendur M. A., Koca N., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.15, no.7, pp.3139-3144, 2014 (SCI-Expanded)
- LXXIX. **Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study**  
Ozdemir N., Abali H., Vural M., YALÇIN Ş., Oksuzoglu B., Civelek B., Oguz D., Bostancı B., Yalcin B., ZENGİN N.  
Cancer Chemotherapy and Pharmacology, vol.74, no.6, pp.1139-1147, 2014 (SCI-Expanded)
- LXXX. **Flurbiprofen-induced unilateral eyelid angioedema**  
ŞENDUR M. A. N., AKSOY S., Özdemir N. Y., Yaman Ş., ZENGİN N.  
Cutis, vol.94, no.4, 2014 (SCI-Expanded)
- LXXXI. **Recurrence risk and prognostic parameters in stage I rectal cancers**  
Cihan S., Kucukoner M., Ozdemir N., Dane F., Sendur M. A. N., Yazilitas D., Urakci Z., Durnali A., Yuksel S., Aksoy S., et al.  
Asian Pacific Journal of Cancer Prevention, vol.15, no.13, pp.5337-5341, 2014 (SCI-Expanded)
- LXXXII. **Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors**  
Yetisigit T., Babacan N., ÜRÜN Y., Seber E. S., Cihan S., Arpacı E., Yildirim N., AKSOY S., Budakoglu B., ZENGİN N., et al.  
Asian Pacific Journal of Cancer Prevention, vol.15, no.2, pp.831-835, 2014 (SCI-Expanded)
- LXXXIII. **Can targeted programmed death-1 antibody be a new treatment approach in breast cancer**  
Sendur M. A. N., AKSOY S., Demirci S., Ozdemir N. Y., ZENGİN N., Altundag K.  
Journal of B.U.ON., vol.19, no.2, pp.584, 2014 (SCI-Expanded)
- LXXXIV. **Lung cancer screening: A comprehensive review of the literature with detailed data Akciğer Kanseri Taraması: Literatürün Güncel Veriler Eşliğinde Detaylı İncelenmesi**  
Acikgoz Y., ŞENDUR M. A. N., Ozdemir N. Y., AKSOY S., ZENGİN N.  
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.24, no.4, pp.270-278, 2014 (SCI-Expanded)
- LXXXV. **Longest survival of lung metastatic ameloblastoma with a rare cause of malignant hypercalcemia**  
Açikgöz Y., Sendur M. A. N., Özdemir N. Y., AKSOY S., Uncu D., ZENGİN N.  
Journal of Cranio-Maxillofacial Surgery, vol.42, no.4, pp.277-278, 2014 (SCI-Expanded)
- LXXXVI. **Serum 25-hydroxy vitamin D status is not related to steopenia/osteoporosis risk in colorectal**

**cancer survivors**

AKINCI M. B., Sendur M. A. N., AKSOY S., Yazici O., Ozdemir N. Y., Kos T., Yaman S., Altundag K., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.15, no.8, pp.3377-3381, 2014 (SCI-Expanded)

- LXXXVII. **Is programmed cell death ligand-1 expression required for optimal response to anti-PD-1 antibody in cancer**

Sendur M. A. N., AKSOY S., Yildirim Ozdemir N., AKINCI M. B., ZENGİN N., Altundag K.  
Journal of B.U.ON., vol.19, no.2, pp.577-578, 2014 (SCI-Expanded)

- LXXXVIII. **Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "charlson Comorbidity Index" and "cumulative Illness Rating Scale"**

Kos F. T., Yazici O., Civelek B., Seker M., ARIK Z., AKSOY S., Uncu D., Ozdemir N., ZENGİN N.  
Wiener Klinische Wochenschrift, vol.126, no.1-2, pp.36-41, 2014 (SCI-Expanded)

- LXXXIX. **Efficacy and safety of first line Vincristine with doxorubicin, bleomycin and dacarbazine (ABOD) for Hodgkin's lymphoma: A single Institute experience**

Ozdemir N., Dogan M., ŞENDUR M. A. N., Yazici O., Abali H., Yazilitas D., AKINCI M. B., AKSOY S., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.15, no.20, pp.8715-8718, 2014 (SCI-Expanded)

- XC. **Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: Phase iii 'stop and go' study results - A turkish oncology group trial**

YALÇIN Ş., Uslu R., Dane F., Yilmaz U., ZENGİN N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S., et al.  
Oncology (Switzerland), vol.85, no.6, pp.328-335, 2013 (SCI-Expanded)

- XCI. **A rare coincidence: Facioscapulohumeral muscular dystrophy and breast cancer**

Yazici O., AKSOY S., Ozdemir N., Sendur M., Dogan M., ZENGİN N.  
Experimental Oncology, vol.35, no.4, pp.311-312, 2013 (SCI-Expanded)

- XCII. **Clinicopathologic features of gastric cancer in young patients**

Seker M., AKSOY S., Ozdemir N., Uncu D., ZENGİN N.  
Saudi Journal of Gastroenterology, vol.19, no.6, pp.258-261, 2013 (SCI-Expanded)

- XCIII. **Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer**

Sendur M., AKSOY S., ZENGİN N., Altundag K.  
Journal of B.U.ON., vol.18, no.4, pp.838-844, 2013 (SCI-Expanded)

- XCIV. **Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients**

Ozdemir N., AKSOY S., Sendur M., Akinci M., Yazici O., Budakoglu B., Abali H., Oksuzoglu B., ZENGİN N.  
Journal of B.U.ON., vol.18, no.4, pp.831-837, 2013 (SCI-Expanded)

- XCV. **Arrhythmias during and after zoledronic acid infusion patients with bone metastasis**

Yazici O., Aksoy S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N., Arik Z., Yaman S., Eren T., Uncu D., et al.  
Medical Oncology, vol.30, no.3, 2013 (SCI-Expanded)

- XCVI. **Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab?**

Sendur M. A. N., AKSOY S., Ozdemir Y., ZENGİN N., Altundag K.  
Journal of B.U.ON., vol.18, no.3, pp.801, 2013 (SCI-Expanded)

- XCVII. **Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients**

Arslan U., Turker I., AKSOY S., Oksuzoglu B., Helvaci K., Yildirim Ozdemir N., Uyeturk U., Uysal Sonmez O., Budakoglu B., ZENGİN N.  
Journal of B.U.ON., vol.18, no.3, pp.585-593, 2013 (SCI-Expanded)

- XCVIII. **Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes**

Kos T., AKSOY S., Sendur M., ARIK Z., Civelek B., Kandemir N., Ozdemir N., ZENGİN N., Altundag K.  
Journal of B.U.ON., vol.18, no.3, pp.608-613, 2013 (SCI-Expanded)

- XCIX. **Evaluation of the renal function using cystatin C level in the patients receiving cisplatin-based chemotherapy**

Kos F., Sendur M., AKSOY S., Sezer S., Civelek B., Yazici O., Yaman S., Eren T., ZENGİN N.

- Renal Failure, vol.35, no.5, pp.705-710, 2013 (SCI-Expanded)
- C. **Breast cancer in octogenarian women: Clinical characteristics and outcome**  
Kuzan T., Koca E., Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., Rahatli S., Dede D., et al.  
Journal of B.U.ON., vol.18, no.2, pp.328-334, 2013 (SCI-Expanded)
- CI. **Tyrosine kinase inhibitors may change the metastatic pattern**  
Sendur M. A. N., AKSOY S., Ozdemir N., ZENGİN N.  
Journal of B.U.ON., vol.18, no.2, pp.544, 2013 (SCI-Expanded)
- CII. **Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: Retrospective analysis of 667 patients anatolian society of medical oncology**  
Uncu D., Aksoy S., Çetin B., Yetişyigit T., Özdemir N., Berk V., Dane F., Inal A., Harputluoglu H., Budakoğlu B., et al.  
Oncology (Switzerland), vol.84, no.4, pp.240-245, 2013 (SCI-Expanded)
- CIII. **Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity**  
Sendur M. A. N., AKSOY S., Yaman S., Arik Z., Tugba Kos F., AKINCI M. B., Civelek B., Yildirim Ozdemir N., Uncu D., ZENGİN N.  
Journal of B.U.ON., vol.18, no.1, pp.274-280, 2013 (SCI-Expanded)
- CIV. **Does zoledronic acid have additive effect on suppression of plasma estrogen levels?**  
Sendur M. A. N., AKSOY S., Özdemir N. Y., Akinci M. B., ZENGİN N., Altundağ K.  
Asian Pacific Journal of Cancer Prevention, vol.14, no.1, pp.607-608, 2013 (SCI-Expanded)
- CV. **Demographic features and factors affecting overall survival in patients with hepatocellular carcinoma: A retrospective analysis in Turkey**  
Uyeturk U., Kos F. T., Helvacı K., Sonmez O. U., Turker I., Aktas G., Budakoglu B., Esbah O., Yalcintasarslan U., Oksuzoglu B., et al.  
Acta Medica Mediterranea, vol.29, no.4, pp.617-623, 2013 (SCI-Expanded)
- CVI. **Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?**  
Sendur M. A. N., Özdemir N. Y., Akinci M. B., Uncu D., ZENGİN N., AKSOY S.  
World Journal of Gastroenterology, vol.19, no.1, pp.144-146, 2013 (SCI-Expanded)
- CVII. **Importance of serum SELDI-TOF-MS analysis in the diagnosis of early lung cancer**  
Şimşek C., Sónmez Ó., YURDAKUL A. S., Ózmen F., ZENGİN N., Keyf A. I., Kubilay D., Gülbahar Ó., Karatayli S. C., Bozdayi M., et al.  
Asian Pacific Journal of Cancer Prevention, vol.14, no.3, pp.2037-2042, 2013 (SCI-Expanded)
- CVIII. **Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy**  
Tugba Kos F., Sendur M. A. N., AKSOY S., Celik H. T., Sezer S., Civelek B., Yaman S., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.14, no.2, pp.1111-1114, 2013 (SCI-Expanded)
- CIX. **Detection of circulating tumor cells in breast cancer patients: Prognostic predictive role**  
Turker I., Uyeturk U., Sonmez O. U., Oksuzoglu B., Helvacı K., Arslan U. Y., Budakoglu B., Alkis N., AKSOY S., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.14, no.3, pp.1601-1607, 2013 (SCI-Expanded)
- CX. **Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use**  
Sendur M. A. N., AKSOY S., Yaman Ş., Arlk Z., Özdemir N. Y., ZENGİN N., Altundağ K.  
Medical Oncology, vol.29, no.4, pp.2601-2605, 2012 (SCI-Expanded)
- CXI. **Is HER2 overexpression sufficient for optimal response to Pertuzumab?**  
Sendur M. A. N., AKSOY S., Yaman Ş., Özdemir N. Y., ZENGİN N.  
Medical Oncology, vol.29, no.4, pp.2565-2566, 2012 (SCI-Expanded)
- CXII. **Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index**  
Sendur M., AKSOY S., ZENGİN N., Altundag K.  
British Journal of Cancer, vol.107, no.11, pp.1815-1819, 2012 (SCI-Expanded)
- CXIII. **Dermatomyositis complicated with a soft tissue sarcoma**  
Sendur M. A. N., AKSOY S., Yaman Ş., Arik Z., Kilinç L., ZENGİN N.

- Rheumatology International, vol.32, no.10, pp.3329-3330, 2012 (SCI-Expanded)
- CXIV. New treatment trends in small cell carcinoma of the urinary bladder**  
Sendur M. A. N., AKSOY S., Yazici O., Akinci M., Ozdemir N., ZENGİN N.  
Journal of B.U.ON., vol.17, no.4, pp.799-800, 2012 (SCI-Expanded)
- CXV. Multiple primary malignant neoplasms: Multi-center results from Turkey**  
Babacan N., Aksoy S., Cetin B., Ozdemir N., Benekli M., Uyeturk U., Ali Kaplan M., Kos T., Karaca H., Oksuzoglu B., et al.  
Journal of B.U.ON., vol.17, no.4, pp.770-775, 2012 (SCI-Expanded)
- CXVI. Frequency of HCV infection in renal cell carcinoma patients**  
Budakoğlu B., Aksoy S., Arslan Ç., Üyetürk Ü., Babacan N. A., Özcan M. F., Yıldız R., Öven B. B., Özdemir N. Y., Dizdar Ö., et al.  
Medical Oncology, vol.29, no.3, pp.1892-1895, 2012 (SCI-Expanded)
- CXVII. Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature**  
Dogan M., Yalcin B., Ozdemir N. Y., Arslan U. Y., Dogan L., UTKAN G., AKBULUT H., ZENGİN N., Alkis N., Icli F.  
Medical Oncology, vol.29, no.3, pp.2021-2026, 2012 (SCI-Expanded)
- CXVIII. Isolated testicular metastasis of gastric cancer**  
Civelek B., Aksoy S., Kös T., Şeker M. M., Arik Z., Şendur M. A. N., Yaman Ş., Cihan Ş., Özdemir N. Y., Uncu D., et al.  
Journal of Gastrointestinal Cancer, vol.43, no.SUPPL. 1, 2012 (SCI-Expanded)
- CXIX. Can bevacizumab be a new treatment approach in metastatic melanoma?**  
Nahit Sendur M. A., Ozdemir N., AKSOY S., Akinci M., ZENGİN N.  
Journal of B.U.ON., vol.17, no.3, pp.601-602, 2012 (SCI-Expanded)
- CXX. Successful treatment of chronic hiccup with baclofen in cancer patients**  
Şeker M. M., AKSOY S., Özdemir N. Y., Uncu D., Civelek B., Akinci M. B., ZENGİN N.  
Medical Oncology, vol.29, no.2, pp.1369-1370, 2012 (SCI-Expanded)
- CXXI. Plasma VEGF levels may not accurately reflect the truth all the time**  
Şendur M. A. N., AKSOY S., Yaman Ş., Arik Z., Özdemir N. Y., ZENGİN N.  
Medical Oncology, vol.29, no.2, pp.1403-1404, 2012 (SCI-Expanded)
- CXXII. Pertuzumab plus trastuzumab in metastatic breast cancer [1]**  
Şendur M. A. N., AKSOY S., ZENGİN N.  
New England Journal of Medicine, vol.366, no.14, pp.1348-1350, 2012 (SCI-Expanded)
- CXXIII. Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey**  
Durnali A., Tokluoğlu S., Özdemir N., İNANÇ M., Alkiş N., ZENGİN N., Sönmez Ö. U., Küçüköner M.  
Asian Pacific Journal of Cancer Prevention, vol.13, no.5, pp.1935-1941, 2012 (SCI-Expanded)
- CXXIV. Abo and rh blood groups and risk of colorectal adenocarcinoma**  
Ürün Y., Özdemir N. Y., Utkan G., Akbulut H., Savaş B., Öksüzoğlu B., Öztuna D. G., Doğan P. I., Yalçın B., Şenler F. Ç., et al.  
Asian Pacific Journal of Cancer Prevention, vol.13, no.12, pp.6097-6100, 2012 (SCI-Expanded)
- CXXV. Is there an association between blood group and survival in pancreatic cancer?**  
Kos F. T., Civelek B., ŞEKER M., ARIK Z., AKSOY S., Uncu D., Ozdemir N., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.13, no.12, pp.6151-6153, 2012 (SCI-Expanded)
- CXXVI. Evaluation of relationship between serum protein profiles and lung cancer by SELDI-TOF-MS (surface enhanced laser desorption ionization time of flight mass spectrometry) method Akciğer kanseri ile serum protein profilleri arasındaki ilişkinin SELDI-TOF-MS (Surface enhanced laser desorption ionization time of flight mass spectrometry) yöntemi ile değerlendirilmesi**  
YURDAKUL A. S., Sönmez Ö., Şimşek C., ZENGİN N., Keyf A. I., ÖZTÜRK C., Öksüzoğlu O. B., Kubilay D., GÜLBAHAR Ö., Özgen Karatayli S. C., et al.  
Turkiye Klinikleri Journal of Medical Sciences, vol.32, no.4, pp.1084-1089, 2012 (SCI-Expanded)
- CXXVII. Taxanes in the adjuvant treatment of node-negative breast cancer patients**  
Ozdemir N., AKSOY S., ZENGİN N., Altundag K.  
Journal of B.U.ON., vol.17, no.1, pp.27-32, 2012 (SCI-Expanded)

- CXXVIII. **Small cell carcinoma of the urinary bladder with hypercalcemia**  
Şendur M. A. N., AKSOY S., Arik Z., Yaman Ş., Özdemir N. Y., Uncu D., ZENGİN N.  
Medical Oncology, vol.29, no.2, pp.827-828, 2012 (SCI-Expanded)
- CXXIX. **Efficacy of angiotensin-receptor blockers on demographic and clinico-pathological characteristics of breast cancer**  
Şendur M. A., AKSOY S., Yaman S., Ozdemir N. Y., ZENGİN N., Altundag K.  
Breast, vol.21, no.3, pp.419-420, 2012 (SCI-Expanded)
- CXXX. **Lymphoproliferative disorders in multiple primary cancers**  
Demirci U., ÖZDEMİR N., Benekli M., Babacan N. A., Cetin B., Baykara M., UĞUR Ş., ZENGİN N., Buyukberber S.  
Asian Pacific Journal of Cancer Prevention, vol.13, no.1, pp.383-386, 2012 (SCI-Expanded)
- CXXXI. **Imatinib-induced anasarca without heart failure: Capillary leakage?**  
Nahit Sendur M., Aksoy S., Civelek B., ZENGİN N., AKSOY S.  
Journal of B.U.ON., vol.17, no.1, pp.188-189, 2012 (SCI-Expanded)
- CXXXII. **Hyperkalemia in a patient with advanced hepatocellular carcinoma probably due to sorafenib: Case report I{cyrillic, ukrainian}lerlemiş hepatoselüler karsinomlu hastada muhtemelen Sorafenibe bağ olan hiperkalemi**  
Üyetürk Ü., Budakoğlu B., Helvacı K., Uysal Sönmez Ö., Türker I., Yalçıntaş Arslan Ü., Öksüzoglu B., ZENGİN N.  
Turkiye Klinikleri Journal of Medical Sciences, vol.32, no.2, pp.585-587, 2012 (SCI-Expanded)
- CXXXIII. **Adjuvant therapy for gallbladder and bile duct cancers: Retrospective comparative study**  
Tugba Kos F., AKSOY S., Odabas H., Ozdemir N., Oksuzoglu B., Uncu D., ZENGİN N.  
Journal of B.U.ON., vol.16, no.3, pp.464-468, 2011 (SCI-Expanded)
- CXXXIV. **Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment**  
Odabas H., Ozdemir N., Isik M., Abali H., Oksuzoglu B., Kos T., Civelek B., Babacan A., Dogan U., ZENGİN N.  
Journal of B.U.ON., vol.16, no.3, pp.460-463, 2011 (SCI-Expanded)
- CXXXV. **Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer**  
Kos F. T., Uncu D., Özdemir N., Budakoglu B., Odabaş H., Abali H., Oksuzoglu B., AKSOY S., ZENGİN N.  
Chemotherapy, vol.57, no.3, pp.230-235, 2011 (SCI-Expanded)
- CXXXVI. **Gemcitabine and cisplatin in patients with carcinoma of unknown primary site**  
Isik M., Seker M. M., Odabas H., Kos F. T., Uncu D., ZENGİN N.  
Medical Oncology, vol.28, no.2, pp.591-596, 2011 (SCI-Expanded)
- CXXXVII. **Long term survival in a metastatic alveolar soft part sarcoma at the time of diagnosis: A case with 17 years of follow-up**  
Kos F. T., Uncu D., Oksuzoglu B., AKSOY S., Ozdemir N., Odabas H., Isik M., Civelek B., ZENGİN N.  
Journal of B.U.ON., vol.16, no.2, pp.376-377, 2011 (SCI-Expanded)
- CXXXVIII. **Gastric adenocarcinoma under the age of 40; more metastatic, less differentiated**  
Isik M., Caner S., Metin Seker M., Civelek B., Odabas H., Ozdemir N., Uncu D., ZENGİN N.  
Journal of B.U.ON., vol.16, no.2, pp.253-256, 2011 (SCI-Expanded)
- CXXXIX. **First-line therapy for metastatic colorectal carcinoma: Modified FOLFOX4 or FOLFIRI-bevacizumab**  
Odabas H., Ozdemir N., Abali H., Oksuzoglu B., Isik M., Uncu D., Cihan S., Seker M., ZENGİN N.  
Journal of B.U.ON., vol.16, no.2, pp.247-252, 2011 (SCI-Expanded)
- CXL. **Breast cancer subtypes and outcomes of central nervous system metastases**  
Arslan U. Y., Oksuzoglu B., AKSOY S., Harputluoglu H., Turker I., Ozisik Y., DİZDAR Ö., Altundag K., Alkis N., ZENGİN N.  
Breast, vol.20, no.6, pp.562-567, 2011 (SCI-Expanded)
- CXLI. **Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma.**  
Cihan Ş., Uncu D., Babacan N. A., Özdemir N., Odabaş H., AKSOY S., Öksüzoglu B., ZENGİN N.  
Asian Pacific journal of cancer prevention : APJCP, vol.12, no.4, pp.967-970, 2011 (SCI-Expanded)
- CXLII. **Bevacizumab: A new potential therapeutic option in sinusoidal obstruction syndrome**  
Şendur M. A. N., AKSOY S., Arik Z., Yaman Ş., Özdemir N. Y., Uncu D., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.12, no.8, pp.2147-2148, 2011 (SCI-Expanded)

- CXLIII. **Rapid pleurodesis in malignant pleural effusion: A clinical study and literature review** Malign plevra efüzyonunda hızlı plörodez: Klinik çalışma ve literatür derlemesi  
Yazkan R., Yildirim E., Dural K., ZENGİN N., Sakinci Ü.  
Turkish Journal of Thoracic and Cardiovascular Surgery, vol.19, no.3, pp.410-416, 2011 (SCI-Expanded)
- CXLIV. **Successful management of bevacizumab-associated surgical bleeding with an ankaferd blood stopper**  
Ozdemir N., AKSOY S., Eren T., Uncu D., Bülent Akinci M., Alaguney M. E., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.12, no.4, pp.1103-1104, 2011 (SCI-Expanded)
- CXLV. **Fifty-one Kaposi sarcoma patients**  
Dogan M., Dogan L., Ozdemir F., Yildirim Ozdemir N., Senol Coskun H., Yalcintas Arslan U., Ozal G., Utakan G., Demirkazik A., Aydin F., et al.  
Clinical and Translational Oncology, vol.12, no.9, pp.629-633, 2010 (SCI-Expanded)
- CXLVI. **The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma**  
Özdemir N. Y., Abali H., Öksüzoglu B., Budakoglu B., Uncu D., Güler T., Odabaşı H., ZENGİN N.  
Medical Oncology, vol.27, no.3, pp.680-684, 2010 (SCI-Expanded)
- CXLVII. **Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma**  
Uncu D., Ozdemir N. Y., AKSOY S., Abali H., Oksuzoglu B. C., Budakoglu B., YILDIZ R., Aslan N., ZENGİN N.  
Asian Pacific Journal of Cancer Prevention, vol.11, no.6, pp.1493-1497, 2010 (SCI-Expanded)
- CXLVIII. **It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting**  
Özdemir N. Y., Abali H., Öksüzoglu B., Budakoğlu B., Akmangit I., ZENGİN N.  
Supportive Care in Cancer, vol.17, no.4, pp.399-403, 2009 (SCI-Expanded)
- CXLIX. **Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes**  
Öksüzoglu B., Abali H., HAYRAN K. M., Yildirim N., Budakoglu B., ZENGİN N.  
Chemotherapy, vol.54, no.5, pp.352-356, 2008 (SCI-Expanded)
- CL. **Prognostic factors and clinicopathological characteristics of carcinoma of ampulla vateri**  
Pamukcuoglu M., Oksuzoglu B., Abali H., Akoglu M., Atalay F., Budakoglu B., Uncu D., Ozdemir N. Y., Guler T., ZENGİN N.  
International Surgery, vol.93, no.4, pp.214-219, 2008 (SCI-Expanded)
- CLI. **Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma**  
Abali H., ÜRÜN Y., Öksüzoglu B., Budakoğlu B., Yıldırım N., Güler T., Özçelik G., ZENGİN N.  
Cancer Investigation, vol.26, no.4, pp.401-406, 2008 (SCI-Expanded)
- CLII. **Intraabdominal desmoplastic small round cell tumor mimicking renal cell cancer: A case report and review of the literature** Böbrek hücreli kanseri taklit eden abdominal kaynaklı desmoplastik küçük yuvarlak hücreli tümör: Bir olgu sunumu ve yayınların gözden geçirilmesi  
Tuncel A., Aslan Y., Yildirim Ü., ZENGİN N., Atan A.  
Turk Uroloji Dergisi, vol.34, no.1, pp.128-132, 2008 (SCI-Expanded)
- CLIII. **Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin**  
KAYA A., UĞUR Ş., ÜNLÜ M., AKDEMİR Ü. Ö., Ozdemir N. Y., ZENGİN N., Benekli M., YILDIZ R., Yaman E., Ozturk B., et al.  
Asian Pacific Journal of Cancer Prevention, vol.9, no.4, pp.683-686, 2008 (SCI-Expanded)
- CLIV. **The effect of regimes of harvesting autologous peripheral stem cell on the number of CD34(+) cell: Experience at a single center** Otolog periferik kök hücre toplama rejimlerinin CD34(+) hücre sayısı üzerine etkisi: Tek merkez deneyimi  
Şahin Balçık Ö., Dağdaş S., Keser Güler S., Özçelik G., Oymak A., Çelik Z., ZENGİN N., Öksüzoglu B., Ayli M., Dinçer S., et al.  
Turkiye Klinikleri Journal of Medical Sciences, vol.28, no.5, pp.640-647, 2008 (SCI-Expanded)

- CLV. **Cerebrovascular accident during cisplatin-based combination chemotherapy of testicular germ cell tumor: An unusual case report**  
Azak A., Öksüzoglu B., Deren T., Öneç B. M., ZENGİN N.  
Anti-Cancer Drugs, vol.19, no.1, pp.97-98, 2008 (SCI-Expanded)
- CLVI. **Good tolerance of high dose cytosine arabinoside and methotrexate after severe myelosuppression secondary to intrathecal administration of the same agents**  
Yildirim N., Abali H., Güler T., Öksüzoglu B., Pamukçu M., ZENGİN N.  
Turkish Journal of Hematology, vol.24, no.3, pp.140-141, 2007 (SCI-Expanded)
- CLVII. **Multiple myeloma in a patient with neurofibromatosis [1]**  
ZENGİN N., Gönül M., Gül Ü., Öksüzoglu B., Kılıç A., Çakmak S. K., Sakinci Ü.  
American Journal of Hematology, vol.82, no.8, pp.772, 2007 (SCI-Expanded)
- CLVIII. **Blood flow indices by doppler ultrasonography vary with neoadjuvant chemotherapy but are not related to plasma VEGF levels in locally advanced breast cancer**  
Öksüzoglu B., Vural M., Abali H., Yilmaz M., Yildirim N., ZENGİN N.  
Oncology, vol.71, no.3-4, pp.185-189, 2007 (SCI-Expanded)
- CLIX. **An extraordinary case in whom gastrointestinal stromal tumor and low-grade malignant lymphoma are seen together in the stomach**  
Pamukcuoğlu M., Budakoğlu B., Han Ö., Tad M., Öksüzoglu B., Abali H., ZENGİN N.  
Medical Oncology, vol.24, no.3, pp.351-353, 2007 (SCI-Expanded)
- CLX. **Tamoxifen induced-thrombocytopenia: It does occur**  
Nasiroğlu N., Pamukcuoğlu M., Abali H., Öksüzoglu B., ÜNER A., ZENGİN N.  
Medical Oncology, vol.24, no.4, pp.453-454, 2007 (SCI-Expanded)
- CLXI. **Cavernous sinus syndrome caused by metastatic colon carcinoma**  
Öneç B., Öksüzoglu B., Hatipoğlu H. G., Öneç K., Azak A., ZENGİN N.  
Clinical Colorectal Cancer, vol.6, no.8, pp.593-596, 2007 (SCI-Expanded)
- CLXII. **Sinonasal NK/T-cell lymphoma mimicking Wegener's granulomatosis: A case report Wegener granülomatozisi taklit eden sinonazal böige tutulumlu NK/T-hücreli lenfoma: Olgu sunumu**  
Pamukcuoğlu M., Nasiroğlu N., Yildirim N., Özçelik Ö., Öksüzoglu B., Abali H., ZENGİN N.  
Tuberkuloz ve Toraks, vol.54, no.3, pp.277-280, 2006 (SCI-Expanded)
- CLXIII. **Prognostic factors of non-Hodgkin lymphoma Non-Hodgkin lenfomada prognostik parametreler**  
Uncu D., Abali H., Özdemir N., Budakoğlu B., Güler T., Öksüzoglu B. Ç., ZENGİN N.  
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.16, no.1, pp.27-31, 2006 (SCI-Expanded)
- CLXIV. **Performance status scales may not correctly predict status of cancer patients with paraplegia**  
Budakoglu B., Abali H., Çakmaköksüzoglu B., AKSOY S., ZENGİN N.  
Cancer Investigation, vol.24, no.2, pp.221-222, 2006 (SCI-Expanded)
- CLXV. **Disclosure of cancer diagnosis to patients and their relatives in Turkey: Views of accompanying persons and influential factors in reaching those views**  
Öksüzoglu B., Abali H., Bakar M., Yildirim N., ZENGİN N.  
Tumori, vol.92, no.1, pp.62-66, 2006 (SCI-Expanded)
- CLXVI. **Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: A randomised phase III trial of Turkish Oncology Group**  
Icli F., Akbulut H., Uner A., Yalcin B., Baltali E., Altinbas M., Coşkun Ş., Komurcu S., Erkisi M., Demirkazik A., et al.  
British Journal of Cancer, vol.92, no.4, pp.639-644, 2005 (SCI-Expanded)
- CLXVII. **Rapid pleurodesis in symptomatic malignant pleural effusion**  
Yildirim E., Dural K., Yazkan R., ZENGİN N., Yildirim D., Gunal N., Sakinci U.  
European Journal of Cardio-thoracic Surgery, vol.27, no.1, pp.19-22, 2005 (SCI-Expanded)
- CLXVIII. **Primary duodenal diffuse large cell non-hodgkin lymphoma with involvement of ampulla of Vater: Report of 3 cases**  
Yildirim N., Öksüzoglu B., Budakoğlu B., Vural M., Abal H., Uncu D., ZENGİN N.  
Hematology, vol.10, no.5, pp.371-374, 2005 (SCI-Expanded)

- CLXIX. **Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis**  
 Budakoglu B., Abali H., Uncu D., Yildirim N., Öksüzoglu B., ZENGİN N.  
*Journal of Chemotherapy*, vol.17, no.4, pp.452-453, 2005 (SCI-Expanded)
- CLXX. **Case report: Cavernous sinus metastasis of the parotid carcinoma: A very unusual case**  
 Yıldırım N., Üksüzoglu B., Vural M., Han Ö., ZENGİN N.  
*Journal of Neuro-Oncology*, vol.73, no.2, pp.181-183, 2005 (SCI-Expanded)
- CLXXI. **Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease**  
 YILDIZ F., ZENGİN N., Engin H., Güllü I., BARIŞTA İ., Çağlar M., Özyar E., CENGİZ M., Gürkaynak M., ZORLU A. F., et al.  
*International Journal of Radiation Oncology Biology Physics*, vol.60, no.3, pp.839-846, 2004 (SCI-Expanded)
- CLXXII. **Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in turkish women: A case-control study**  
 Oran B., ÇELİK İ., ERMAN M., Baltali E., ZENGİN N., DEMİRKAZIK F., Tezcan S.  
*Medical Oncology*, vol.21, no.1, pp.31-39, 2004 (SCI-Expanded)
- CLXXIII. **Use of hydroxyurea and  $\alpha$ -interferon in chronic myeloid leukemia during pregnancy: A case report**  
 Baykal C., ZENGİN N., COŞKUN F. M., Güler N., Ayhan A.  
*European Journal of Gynaecological Oncology*, vol.21, no.1, pp.89-90, 2000 (SCI-Expanded)
- CLXXIV. **Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy**  
 Barişta I., Tekuzman G., Yalçın Ş., Güllü I., Güler N., Özışık Y., Kars A., Çelik I., Türker A., Altundağ K., et al.  
*Journal of Surgical Oncology*, vol.73, no.1, pp.12-16, 2000 (SCI-Expanded)
- CLXXV. **Paclitaxel in the salvage treatment of metastatic breast carcinoma**  
 Guler N., Baltali E., Altundag K., ZENGİN N., Tekuzman G., Ozisik Y., Firat D.  
*Journal of B.U.ON.*, vol.4, no.3, pp.275-281, 1999 (SCI-Expanded)
- CLXXVI. **Acute lymphoblastic leukaemia presenting with arthritis in an adult patient**  
 Usalan C., Özarslan E., ZENGİN N., Büyükaýk Y., Güllü Y. H.  
*Postgraduate Medical Journal*, vol.75, no.885, pp.425-427, 1999 (SCI-Expanded)
- CLXXVII. **The significance of the bone marrow biopsy pattern in chronic lymphocytic leukemia: A prognostic dilemma**  
 ZENGİN N., Kars A., Sungur A., Zengin N. I., HAYRAN K. M., Tekuzman G., Kansu E., Ruacan Ş., Firat D.  
*American Journal of Hematology*, vol.62, no.4, pp.208-211, 1999 (SCI-Expanded)
- CLXXVIII. **Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma**  
 Kars A., Çelik I., Kansu E., Tekuzman G., Özışık Y., Güler N., Barişta I., Güllü I., Yalçın Ş., Altundağ K., et al.  
*European Journal of Haematology*, vol.59, no.2, pp.100-104, 1997 (SCI-Expanded)
- CLXXIX. **Primary neuroendocrine tumor of the breast**  
 YALÇIN Ş., ZENGİN N., Tekuzman G., Küçükali T.  
*Medical Oncology*, vol.14, no.2, pp.121-123, 1997 (SCI-Expanded)
- CLXXX. **High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas**  
 Güllü I., YALÇIN Ş., Tekuzman G., BARIŞTA İ., Alkiş N., ÇELİK İ., ZENGİN N., Güler N., Kars A., Baltali E., et al.  
*Cancer Investigation*, vol.14, no.3, pp.239-242, 1996 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Squamous cell cancer of the lung with synchronous renal cell carcinoma**  
 Ateş İ., Yazıcı O., Ateş H., Yazılıtaş D., Özcan A. N., Ağaçkuran Y., ZENGİN N.  
*Turk Toraks Dergisi*, vol.17, no.3, pp.125-127, 2016 (ESCI)
- II. **Clinical outcomes and prognostic factors of adult's Ewing sarcoma family of tumors: Single center experience**  
 Uyeturk U., Helvacı K., Demirci A., Sonmez O. U., Turker I., Afsar C. U., Budakoglu B., Arslan U. Y., Oksuzoglu O. B.,

- ZENGİN N.  
Wspolczesna Onkologia, vol.20, no.2, pp.141-146, 2016 (ESCI)
- III. Evaluation of the effects of red blood cell distribution width on survival in lung cancer patients  
Kos M., Hocazade C., Kos F. T., Uncu D., Karakas E., Dogan M., Uncu H. G., Ozdemir N., ZENGİN N.  
Wspolczesna Onkologia, vol.20, no.2, pp.153-157, 2016 (ESCI)
- IV. Helicobacter pylori seropositivity of colon cancer Kolon Kanserinde Helikobakter Pylori Seropozitifliği  
Tuğba Köş F., Sezer S., Yazıcı O., Civelek B., Yıldız A., AKSOY S., Özdemir N., Uncu D., Akıncı B., ZENGİN N.  
Journal of Clinical and Analytical Medicine, vol.6, no.1, pp.79-82, 2015 (ESCI)
- V. Methodology of National Turkey Nutrition and Health survey (TNHS)  
BESLER H. T., PEKCAN A. G., ZENGİN N., BAKIR F.  
Medical Journal of Islamic World Academy of Sciences, vol.22, no.1, pp.7-29, 2014 (Peer-Reviewed Journal)
- VI. Clinical features and prognostic factors of hepatocellular carcinoma patients; single center experience  
ALANLI R., KÖŞ F. T., UNCU D., YAZICI O., ÖZDEMİR N., AKSOY S., YILMAZ N., ABAYLI E., ZENGİN N.  
TÜRK ONKOLOGİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.28, no.4, pp.143-149, 2013 (ESCI)
- VII. Primary squamous cell carcinoma of the breast  
Uncu D., Öksüzoglu B., Budakoğlu B., Günece S., Özdemir N., Güler T., ZENGİN N.  
Turkish Journal of Cancer, vol.39, no.1, pp.26-27, 2009 (Scopus)
- VIII. The clinical and pathological features of patients with gastric cancer in Turkey: A Turkish Oncology Group Study  
Yalçın B., ZENGİN N., AYDIN F., İlhan M., Işıkdoğan A., Demir G., Aykan F., ÇELİK İ., Dane F., Üstüner Z., et al.  
Turkish Journal of Cancer, vol.36, no.3, pp.108-115, 2006 (Scopus)
- IX. Primary extranodal lymphoma: The comparison of clinical characteristics with nodal lymphoma  
Primer ekstranodal lenfomalar: Klinik özelliklerinin nodal lenfomalarla karşılaştırılması  
Uncu D., Özdemir N., Karakan Ş., Öksüzoglu B. Ç., ZENGİN N.  
THOD - Turk Hematoloji-Onkoloji Dergisi, vol.15, no.2, pp.63-67, 2005 (Scopus)
- X. Retrospective Evaluation of Adults with Soft Tissue Ewing Sarcoma and Primitive Neuroectodermal Tumors Yumuşak Doku Ewing Sarkomu ve Primitif Nöroektodermal Tümörlü Erişkin Olguların Retrospektif Değerlendirilmesi  
Karakan Ş., Öksüzoglu B., Uncu D., Yıldırım N., Budakoğlu B., Küçükazman M., Genç H., Akdur S., ZENGİN N.  
THOD - Turk Hematoloji-Onkoloji Dergisi, vol.14, no.1, pp.14-19, 2004 (Scopus)
- XI. Docetaxel (Taxotere) in the salvage treatment of anthracycline resistant metastatic breast cancer  
Guler N., Baltali E., Altundag K., ZENGİN N., Ozisik Y., Tekuzman G., Firat D.  
Turkish Journal of Cancer, vol.29, no.3, pp.119-129, 1999 (Scopus)

## Metrics

Publication: 191  
Citation (WoS): 1116  
Citation (Scopus): 1327  
H-Index (WoS): 17  
H-Index (Scopus): 18

## Artistic Activity

ZENGİN N., 6. Umudun Renkleri Sergisi, September 2017  
ZENGİN N., Numuneli Ressamlar 8. Hastane Sergisi, June 2017  
ZENGİN N., Türkiye'nin Renkleri Resim Sergisi, May 2017

ZENGİN N., GÜZEL ÜLKEM TÜRKİYE / MON BEAU PAYS TURQUIE, April 2017

ZENGİN N., Dünya Böbrek Günü Farkındalık Toplantısı ve Gönülden Destek Projesi El Sanatları Sergisi, March 2017